LH logo

LabCorp

LH · What the business does, what can go wrong, and how options sellers approach it

What it does

Labcorp is a global life sciences and diagnostics company. It runs a large network of labs and patient service centers that test blood, urine and tissue samples. Results help doctors diagnose, monitor and treat disease.

The company also has a biopharma laboratory services business that performs testing for drug developers.

How it makes money

Labcorp earns fees for testing. Payers include commercial health insurers, government programs such as Medicare and Medicaid, hospitals and patients.

Its biopharma laboratory services business earns fees from pharmaceutical and biotech clients for work such as central lab and early development testing, often under long contracts.

Routine testing is high volume and fairly steady. Specialty tests, such as oncology and genetic testing, tend to be more complex and can carry higher value per test.

Why investors own it

  • Testing demand is tied to healthcare use, which tends to be less sensitive to the economic cycle than many industries.
  • Scale in a business with large fixed costs can help efficiency and bargaining with payers.
  • Diversification across diagnostics and biopharma laboratory services gives it more than one source of revenue.
  • Cash generation may support reinvestment, buybacks and dividends, though none are guaranteed.

What can go wrong

  • Reimbursement rates set by insurers and government programs can be cut or reformed, which pressures pricing.
  • Competition from large national labs, hospital systems and smaller specialty labs can limit pricing and volume.
  • Biotech funding swings can slow demand in the biopharma laboratory services business.
  • Acquisitions can bring integration problems and added debt.
  • Regulation, data privacy rules and billing compliance create legal and operating risk.

What to watch

  • Testing volumes and revenue per test
  • Organic growth by segment
  • Operating margin trends
  • Biopharma laboratory services backlog and cancellations
  • Changes in Medicare and insurer reimbursement policy
  • Debt levels, capital allocation and integration of acquired labs

Options income angle

Options on LH are usually reasonably liquid, though trading is lighter than in mega-cap stocks, so spreads can be wider on less active strikes.

Implied volatility tends to rise ahead of quarterly earnings and around reimbursement or industry news, then often eases.

One caution: an earnings or policy surprise can push the stock well past a short strike, so sellers of covered calls or cash-secured puts should understand assignment risk.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 24, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Labcorp reported revenues of $13,951.7 million for 2025, up 7.2%, and operating income of $1,384.7 million, up 27.4%. Growth came from both its diagnostics business (Dx) and its drug development services business (BLS). The risk section highlights a large patent verdict under appeal, Medicare lab price cuts that resume in 2027, and $5.2 billion of senior notes.

How the business did

  • Revenues rose to $13,951.7 million from $13,008.9 million. Organic growth (revenue excluding acquisitions, divestitures and currency) was 4.4%, acquisitions net of divestitures added 2.5%, and currency added 0.4%.
  • Dx revenue was $10,876.5 million, up 7.2%, and test requisitions (orders) rose 3.7%. BLS revenue was $3,098.2 million, up 6.0%. Dx segment operating income was $1,779.9 million and BLS was $498.5 million.
  • Cost of revenues fell to 71.2% of revenues from 72.1%, and selling, general and administrative expenses fell to 15.9% from 17.1%. Management credited efficiencies and revenue growth, including the performance of Invitae. Restructuring charges rose to $127.2 million, including $105.5 million tied to the restructuring of ED.
  • "Other, net" moved to a loss of $55.0 million from a gain of $60.2 million, mainly because fees charged to Fortrea for transition services ended when the agreement expired on June 30, 2025.
  • Operating cash flow was $1,640.5 million. Capital expenditures were $434.5 million and dividends paid were $240.7 million. Cash and cash equivalents ended the year at $532.3 million, down from $1,518.7 million.

Risks specific to this company

  • Ravgen patent case: A jury awarded Ravgen $272.0 million in 2022. The court later added $100.0 million in enhanced damages, $2.6 million in supplemental damages, and an ongoing royalty of $100 per test. The company disagrees and is appealing.
  • Medicare lab pricing: Cuts under PAMA (a law that resets Medicare lab test rates) are frozen for 2026 but resume in 2027, capped at 15% per year for 2027-2029. Further reductions could follow.
  • Debt: Senior notes total $5.2 billion in principal, with $500.0 million due within 12 months. A $1.0 billion revolving credit facility requires the company to stay within a leverage ratio limit.
  • BLS exposure: BLS revenue depends on drug and device companies' R&D spending, and many of its contracts can be cut or cancelled. It also bears the cost if fixed-price contracts run over budget, and it earns a significant portion of its revenue outside the U.S.
  • Insurance coverage changes: The July 2025 OBBBA law changes Medicaid and the ACA and could reduce insurance coverage and testing demand. Management does not expect a material effect.
  • Acquisition strategy: The company has invested net cash of approximately $3.8 billion in acquisitions since January 1, 2021. Integration problems, lost customers or goodwill write-downs could follow.

What management is watching

  • Spending: Capital expenditures were 3.1% of revenues in 2025, and management expects 4.0% in 2026. The increase covers growth projects, facility expansion, the LaunchPad initiative and acquisition integration.
  • Pending deals: The company expects to pay up to $415.0 million for Empire City laboratory assets and Parkview Health System outreach assets, including $85.0 million contingent on performance. Empire City closed in the first quarter of 2026, and Parkview is expected to close in 2026.
  • Financing: Of total future debt payments of $5,622.6 million, $500.3 million is payable within 12 months, and management anticipates refinancing it. The receivables facility was amended on January 28, 2026 and extended to January 26, 2029.
  • Capital return: A dividend of $0.72 per share was announced on January 14, 2026, about $61.0 million in total. $830.4 million remains under the share repurchase authorization.
  • Measures cited: Management points to organic growth, Dx requisition volume and price/mix, and segment operating margins (16.4% for Dx and 16.1% for BLS).

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Labcorp reported third-quarter revenues of $3,810.0 million, up 6.9% from the same quarter in 2025, and profit margins improved in both of its segments. After quarter-end the company announced several acquisitions, and it says it expects to refinance $600.0 million of senior notes at higher interest rates.

How the business did

  • Revenue: Third-quarter revenues were $3,810.0 million versus $3,563.5 million a year earlier. Organic growth (which strips out acquisitions, divestitures and currency) was 5.5%. For the nine months, revenues were $11,078.7 million, up 6.2%.
  • Segments: Dx (diagnostics) revenues were $2,948.9 million, up 6.5%, with test volume measured by requisitions up 4.8%. BLS revenues were $866.7 million, up 8.5%. Operating margin rose to 16.7% in Dx from 16.3%, and to 18.3% in BLS from 16.5%, helped by efficiencies from strategic actions in ED.
  • Profit: Total operating income was $402.1 million versus $396.6 million, up 1.4%. SG&A (overhead) rose to 16.0% of revenues from 15.5%, on higher personnel costs and LaunchPad initiatives. General corporate expenses were $153.9 million versus $110.6 million. The tax rate fell to 19.8% from 22.4%, mainly from releasing uncertain tax positions tied to U.S. research and development tax credits. For the nine months, operating income was $1,234.5 million, up 10.5%.
  • Cash and capital return: Nine-month operating cash flow was $1,200.8 million versus $1,026.3 million. Capital expenditures were $404.2 million, and dividends paid were $178.1 million. On July 8, 2026 the Board authorized an additional $1,000.0 million of share repurchases, leaving $1,378.6 million of authorization at quarter-end. Cash was $261.8 million.

What management is watching

  • Acquisitions: The company agreed to buy select BioReference Health laboratory assets from OPKO for up to $872.0 million (expected to close mid-2027), Myriad's Prenatal Health business for approximately $210.0 million in cash (early 2027), and Millennium Health for up to $375.0 million (2026). A separate outreach laboratory deal of approximately $155.0 million was agreed on June 28, 2026.
  • Debt and interest costs: The 2026 Term Loan, the AR Facility and the revolving credit facility carry variable rates, so higher benchmark rates would raise interest expense. Management expects the $600.0 million 3.60% senior notes due September 1, 2027 to be replaced by debt at higher rates. It says liquidity is sufficient and that it was in compliance with all covenants.
  • Healthcare policy: Management says changes to Medicaid and the Affordable Care Act under the OBBBA could reduce insurance coverage and testing volumes. It does not believe the effect would likely be material, and it will keep evaluating as provisions take effect through 2028.

New or changed risks

  • ERP rollout: The company is extending a new ERP (enterprise resource planning) system across more of the business. It warns this could cost more than expected and disrupt supply chain and procurement, cause data errors, or hinder transaction processing.
  • Inventory and cash: To extend the system and avoid supply disruptions, the company may increase or accelerate inventory purchases, which could hurt cash flows and liquidity.
  • Vendors and acquired businesses: The risk factor now stresses that failures at third-party providers (transportation, supplies, data processing) or in newly acquired businesses' systems could disrupt services or expose confidential information, even if the company is not responsible for the cause.

Follow LH in Kortex

The Kortex app shows LH's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.